The RCC biomarker field is gathering steam. Stellar review of the field by VUMC Fellow Matthew Tucker here: bit.ly/rccbiomarkers
- Updated table of the latest data for initial IO-based therapy in IMDC Int/Poor mRCC. See thread for discussion of imperfections and thoughts.
- Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. @montypal @DrChoueiri @tompowles1 @motzermd @HHammersMD
- An updated table of the front-line IO combination RCC studies that have shown an OS advantage.
- New table of IO doublets in sarcomatoid RCC: 1. Central path review done for ipi/nivo while other datasets relied on local path report 2. IO/VEGF with very short f/u and thus wide CIs 3. Ipi/nivo notable for high CR rate and high landmarks with long f/u 4. No detailed CLEAR data
- Why does PD-1-based therapy have superior outcomes in RCC? To me the clinical data are clear. All PD-1-based trials positive for OS, all PD-L1-based trials are negative. Summary data for IO/TKI trials here:
- Nick was an inspiration to me since I was a Medicine Resident on his service in 1998. He is the reason I became a GU Oncologist. He made me a better doctor and a better person. Calling him a legend doesn't seem nearly enough. Rest in peace my friend. spotifyanchor-web.app.link/e/YdxukdcVwtb
- Updated table of IO doublets in mRCC after #ASCOGU22: 1. Consistent OS benefit; medians immature for IO/TKIs 2. IO/TKIs with more tumor shrinkage; higher ORR, longer PFS and less early PD 3. Ipi/Nivo has the most durable benefit at 5 years -IO/TKI data immature
- New table highlighting results in IMDC favorable risk RCC across IO-based doublets and nivo/pembro monotx trials. Major caveats about small subsets and differing follow-up, but interesting observations emerge. Thanks to @DrChoueiri and Mike Atkins for help assembling data.
- Updated table of IO combos (ITT population) in front line mRCC after #ASCOGU24. Has anything changed for you based on these data?
- Updated table of OS-improving IO-based combinations in mRCC. Some details pending #ASCOGU presentations and publications. Much to discuss. #uromigospodcasts
- Updated table post ASCO 2021. Best to focus on building on these combos to cure more patients than on comparing across regimens.
- Updated summary after #ESMO21. Thanks to @ERPlimackMD for help. Not well-captured are some of the durable benefits of Ipi/nivo. Note median OS nearing 5 years! Awaiting mature data for IO/TKI regimens. Let's move to biomarker-based designs and not argue regimen A vs regimen B.
